Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Andreas Pintera Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, GermanyView further author information

Kilian Eyerichb Department of Dermatology and Venerology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany;c Karolinska Institutet and Karolinska University Hospital, Stockholm, SwedenView further author information

Antonio Costanzod Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy;e Dermatology, Humanitas Research Hospital IRCCS, Rozzano, Milan, ItalyView further author information

Alyssa Garreltsf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

Christopher Schusterf Eli Lilly and Company, Indianapolis, Indiana, USA;g Department of Dermatology, Medical University of Vienna, Vienna, AustriaView further author information

Can Merth HaaPACS GmbH, Schriesheim, GermanyView further author information

Anastasia Lampropoulouf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

Konstantinos Fotiouf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

Julia-Tatjana Mauli Department of Dermatology, University Hospital Zurich, Zurich, Switzerland;j Faculty of Medicine, University of Zürich, Zurich, SwitzerlandView further author information

Kim A. Pappk Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada;l Division of Dermatology, Department of Medicine, University of Toronto, Ontario, CanadaCorrespondence[email protected]

https://orcid.org/0000-0001-9557-3642 View further author information

show all

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date